CLL update 2022: A continuing evolution in care
NE Kay, PJ Hampel, DL Van Dyke, SA Parikh - Blood Reviews, 2022 - Elsevier
Chronic lymphocytic leukemia (CLL) is diagnosed by the presence of a specific
immunophenotype of clonal B cells in the peripheral blood. Prognostic models such as the
CLL-International Prognostic Index (CLL-IPI) are now available that evaluate risk and assist
in counseling individual patients. High risk CLL is characterized as the presence of
del17p13, TP53 mutations and complex karyotype. Multiple phase 3 clinical trials show that
continuous therapy with novel agents such as Bruton tyrosine kinase inhibitors (BTKi) and B …
immunophenotype of clonal B cells in the peripheral blood. Prognostic models such as the
CLL-International Prognostic Index (CLL-IPI) are now available that evaluate risk and assist
in counseling individual patients. High risk CLL is characterized as the presence of
del17p13, TP53 mutations and complex karyotype. Multiple phase 3 clinical trials show that
continuous therapy with novel agents such as Bruton tyrosine kinase inhibitors (BTKi) and B …
以上显示的是最相近的搜索结果。 查看全部搜索结果